Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus
Capricor Therapeutics (CAPR) shares rose 17% after positive clinical data. Iovance Biotherapeutics (IOVA) gained 31% on raised revenue outlook. DraftKings (DKNG) fell 7% amid competitor funding news. Trade Desk (TTD) declined on revenue growth concerns. Dow is down for Q3, while S&P 500 and Nasdaq are up. PCE data release expected to impact markets.
How this was made
The 30-second read
Why it matters
The article provides first‑report data on a biotech trial, a revenue outlook raise, and competitive financing news, each driving notable intraday moves.
Market read
Four U.S. listed companies experience sizable price moves tied to fresh, material news, offering short‑term trading opportunities.
What to watch
Potential regulatory delays for CAPR trial and macro‑economic pressure on ad spend could temper gains.
Background
A market‑watch style piece highlighting several stocks with fresh catalysts and price moves.
Ticker impact
Shares surged >17% after Capricor reported new Hope-3 extension data showing slower upper‑limb deterioration.
likely further upside as investors price in clinical progress
Data is fresh, first report, and directly linked to a large intraday move.
Iovance shares jumped >31% after the company raised its 2026 revenue outlook.
upward pressure as outlook exceeds expectations
First disclosure of the outlook lift, driving a sizable price jump.
DraftKings fell >7% following reports that competitor Kalshi is in advanced talks for a $1 billion financing round.
likely further decline as market worries about competition
News is new and linked to a notable price drop.
The Trade Desk declined after weaker‑than‑expected revenue growth and concerns over programmatic ad spend.
downward pressure as investors reassess ad‑spend outlook
First report of the revenue miss and its impact on price.
Market effects
Biotech trial data and outlook upgrades may lift sector sentiment; ad‑tech weakness could weigh on broader tech.
U.S. equity futures mixed; biotech gains offset tech declines in early trade.
Limited to U.S. markets; no immediate global macro impact.
Counterpoint
Biotech hype may be overstated; investors could profit from shorting on later data disappointments.
Key entities
- companyCapricor Therapeutics
Biotech firm reporting trial data.
- companyIovance Biotherapeutics
Biotech firm raising revenue outlook.
- companyDraftKings
Sports‑betting platform affected by competitor financing news.
- companyThe Trade Desk
Ad‑tech firm facing weaker revenue outlook.
